Acute coronary syndrome
Conditions
Interventions
Evolocumab group:Inject 140 mg of Evolocumab subcutaneously, once every two weeks
Alirocumab group:Inject 140 mg of Alirocumab subcutaneously, once every two weeks
Sponsors
Zhongda Hospital affiliated to Southeast University
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years old; 2. Clear diagnosis of ACS and undergo PCI intervention; 3. Sign the informed consent form and be willing to cooperate in the entire research process.
Exclusion criteria
Exclusion criteria: 1. Hemodynamic or electrocardiographic instability; 2. Allergic to research drugs and their ingredients; 3. The subject has received PCSK9 inhibitor treatment or participated in other studies that inhibit PCSK9; 4. Patients with severe renal insufficiency, eGFR < 30mL/min/1.73m2, 5. With obstructive jaundice, active liver disease, chronic hepatitis, AST or ALT exceeds the upper limit of normal by 3 times; 6. Women during pregnancy or lactation; 7. End-stage tumor; 8. Septic shock, connective tissue disease, blood system disease, diabetic ketosis or hyperosmolar coma;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet Aggreation; | — |
Countries
China
Contacts
Public ContactYan Gaoliang
Zhongda Hospital of Southeast University
Outcome results
None listed